Search
Unasnemab
go.drugbank.com/drugs/DB18837InvestigationalUnasnemab is under investigation in clinical trial NCT04683848 (Study to Assess the Efficacy and Safety of MT-3921 in Subjects With Acute Traumatic Cervical Spinal Cord Injury).
Cardiopet
go.drugbank.com/drugs/DB18913InvestigationalCardiopet is under investigation in clinical trial NCT01826773 (Cardiopet as PET Imaging Agent to Assess Myocardial Perfusion and Fatty Acid Uptake in Known or Suspected CAD Subjects).
SAR-125844
go.drugbank.com/drugs/DB15382InvestigationalSAR-125844 is under investigation in clinical trial NCT01391533 (Study of SAR125844 Single Agent Administered as Slow Intravenous Infusion in Adult Patients With Advanced Malignant Solid Tumors).
Amperozide
go.drugbank.com/drugs/DB08927ExperimentalAmperozide is a diphenylbutylpiperazine atypical antipsychotic which antagonizes 5-HT2A receptors. It inhibits dopamine release and alters the firing of dopaminergic neurons. … Alternatively, amperozide's main use lies in veterinary medicine, where it is typically employed to minimize aggression and stress in intensively farmed pigs.
Temocapril
go.drugbank.com/drugs/DB08836InvestigationalTemocapril is a prodrug-type angiotensin-I converting enzyme (ACE) inhibitor not approved for use in the United States, but is approved in Japan and South Korea.
ACE393
go.drugbank.com/drugs/DB05071InvestigationalACE393 is an injectable vaccine designed to combat the bacterium Campylobacter jejuni, one of the greatest causes of bacterial diarrhoeal infections in the developed world.
7,8-dihydrobiopterin
go.drugbank.com/drugs/DB04400Experimental7,8-Dihydrobiopterin is an inhibitor of the enzyme dihydroneopterin aldolase (DHNA), which catalyzes the conversion of 7,8-Dihydrobiopterin to 6-hydroxymethyl-7,8-dihydropterin and glycolaldehyde.
Hycanthone
go.drugbank.com/drugs/DB14061ExperimentalPotentially toxic, but effective antischistosomal agent, it is a metabolite of LUCANTHONE. Hycanthone was approved by the FDA in 1975 but is no longer used.
Emactuzumab
go.drugbank.com/drugs/DB14905InvestigationalEmactuzumab is under investigation in clinical trial NCT01494688 (A Study of RO5509554 as Monotherapy and in Combination With Paclitaxel in Participants With Advanced Solid Tumors).